Bcl-2 / Bcl-xL

Class

Dual Bcl-2/Bcl-xL inhibitor (prodrug small molecule; converted to active metabolite APG-1252-M1 in tumor tissue)

Pathway

Disrupts Bcl-xL/Bax and Bcl-xL/Bak complexes, releasing pro-apoptotic proteins and activating downstream apoptosis (PARP-1/caspase-3 cleavage)

Bcl-2 and Bcl-xL are members of a family of proteins that control the intrinsic, or mitochondrial, pathway of apoptosis (programmed cell death). Under normal conditions they act as guardians, binding and neutralizing pro-apoptotic proteins such as Bax and Bak so that cells survive. Many cancers exploit this by overexpressing Bcl-2 and Bcl-xL, allowing malignant cells to evade death signals that would otherwise be triggered by DNA damage or oncogenic stress. Small molecules known as BH3 mimetics are designed to occupy the binding groove on these survival proteins, displacing Bax and Bak so they can permeabilize the mitochondrial membrane and commit the cell to apoptosis. A dual inhibitor that blocks both Bcl-2 and Bcl-xL addresses tumors that rely on either or both proteins for survival, broadening potential efficacy compared with an agent selective for only one. This approach is relevant across various blood cancers and some solid tumors where resistance to standard therapies is often linked to elevated Bcl-2 family activity. Because these proteins are also important for the survival of certain normal cells, particularly platelets, modulating this pathway carries inherent biological trade-offs that shape how such agents are designed and dosed.